GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+3.36 (+2.77%)
As of 12:44PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close121.21
Bid124.81 x 800
Ask125.02 x 900
Day's Range121.25 - 126.14
52 Week Range105.12 - 179.65
Avg. Volume579,856
Market Cap4.029B
Beta (3Y Monthly)4.01
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.09
Trade prices are not sourced from all markets
  • Cannabis markets are expected to grow by 700 percent by 2020: RPT
    Yahoo Finance Video13 days ago

    Cannabis markets are expected to grow by 700 percent by 2020: RPT

    A health drink company called New Age Beverages is cashing in on the ongoing cannabis craze. Yahoo Finance’s Alexis Christoforous speaks to the CEO of New Age Beverages Brent Willis.

  • Weed is on the ballot in these 5 states
    Yahoo Finance Video16 days ago

    Weed is on the ballot in these 5 states

    Cannabis is on the ballot in several states across the U.S. tomorrow. Yahoo Finance's Alexis Keenan breaks it down for views.

  • GlobeNewswire2 days ago

    GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that results from completed Phase 3 trials of EPIDIOLEX® (cannabidiol) oral solution CV, as well as new pre-clinical and Phase 1 cannabinoid research, will be presented at the American Epilepsy Society (AES) Annual Meeting, November 30-December 4, 2018, in New Orleans, Louisiana. EPIDIOLEX is FDA-approved and available by prescription in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.

  • ACCESSWIRE2 days ago

    4 Marijuana Stocks Expanding Across North America

    China trade and the looming Russia medalling that continues to surround the White House have had a wild impact on markets. One industry that is not only used to volatility but one that is also seeing growing interest from investors has been the cannabis industry. Slated as an expanding sector, marijuana stocks have had a long-standing role in the spotlight for its risqué impact on society.

  • 4 Lit Marijuana Stocks to Buy
    Kiplinger5 days ago

    4 Lit Marijuana Stocks to Buy

    Cannabis is a hugely exciting market right now. Marijuana stocks are surging following multiple positive regulatory movements: Utah and Missouri voters both just passed resolutions to legalize medical cannabis, Michigan voted to green-light recreational marijuana and outspoken anti-cannabis Attorney General Jeff Sessions has now resigned. Meanwhile, Canada recently became the first major world economy to legalize cannabis for both medical and recreational use. It's not clear whether the U.S. will follow in our neighbor's footsteps. What is clear is that pro-marijuana legislation is spreading, and marijuana-friendly policies at least feel a little more likely with a Democratic majority in the U.S. House of Representatives. Bear in mind, 70% of Democrats support marijuana legalization vs just 45% of Republicans. Here are the top marijuana stocks to buy if you want to take advantage of these latest developments. We use TipRanks' market data to pinpoint four of the most promising marijuana stocks out there. As you will see, all four of these stocks have a consensus "Buy" rating from Wall Street's best minds. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)

  • Trulieve to Announce Q3 Earnings on November 19!
    Market Realist5 days ago

    Trulieve to Announce Q3 Earnings on November 19!

    Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET. Analysts expect Trulieve to report revenues of 35.1 million Canadian dollars for the third quarter of 2018. Trulieve is a vertically integrated cannabis company involved in the cultivation, production, and commercialization of cannabis products in the State of Florida.

  • Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
    Market Realist5 days ago

    Curaleaf Opens Medical Marijuana Dispensary in Tallahassee

    Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.

  • Benzinga6 days ago

    What Is CBD — And How Can Investors Take Advantage Of It?

    CBD, which is short for cannabidiol, is the second-most present ingredient in marijuana. Cannabidiol is one of more than 100 discovered components in marijuana that are commonly known as cannabinoids. The research into the benefits of CBD is fairly new, and the conditions and symptoms it can treat are still being discovered.

  • Benzinga7 days ago

    4 Reasons Why Leerink Is Bullish On GW Pharma

    Leerink is taking a bullish stance on  GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH ), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy ...

  • WeedMD Secures Cannabis Sales License from Health Canada
    Market Realist7 days ago

    WeedMD Secures Cannabis Sales License from Health Canada

    WeedMD (WMD) is a Canada-based licensed producer of medical marijuana. On November 13, the company announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario. The below chart lists some key highlights of WeedMD’s greenhouse. According to the company’s press release, the original license, which was issued under the Access to Cannabis for Medical Purposes regulations, was migrated to the license issued under the Cannabis Act regulations.

  • MarketWatch7 days ago

    GW Pharma initiated at Leerink with 'outperform' rating

    Leerink initiated coverage of GW Pharmaceuticals PLC ADR early Wednesday with an "outperform" rating and a price target of $185. GW Pharma develops medications that use cannabinoids, the chemical compounds in marijuana, and shares of the company closed at $132.18 on Tuesday. "We like new epilepsy drugs," Leerink analyst Marc Goodman said, predicting blockbuster sales of the company's lead product, Epidiolex, which has been approved in the U.S. for seizures associated with two rare types of childhood epilepsy. Goodman was also bullish on GW Pharma's second product, Sativex, which is intended for the muscle tightness and spasms that are symptoms of multiple sclerosis and has been approved in other countries, though not in the U.S. so far. The analyst said that Sativex "receives minimal attention" but could bring in global sales of $340 million by the end of 2030. "Epilepsy is a high operating margin business model, so our sales forecasts should drive strong bottom-line profits," Goodman said. "The company's deep cannabinoid science platform and proprietary know-how in this area should enable it to develop additional products to sustain growth." GW Pharma shares were not active in premarket trade. Shares have dropped nearly 4% month-to-date, compared with a 0.4% rise in the S&P 500 .

  • What to Expect from Cannabis Player Curaleaf’s Q3 Earnings
    Market Realist8 days ago

    What to Expect from Cannabis Player Curaleaf’s Q3 Earnings

    Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.

  • ACCESSWIRE8 days ago

    Election Night Cannabis Approvals Could Benefit These Companies

    HENDERSON, NV / ACCESSWIRE / November 13, 2018 / Last Tuesday's election was great news for cannabis companies. With Michigan approving recreational marijuana and several other measures passing investors ...

  • Why GW Pharmaceuticals Stock Dropped 20% in October
    Motley Fool11 days ago

    Why GW Pharmaceuticals Stock Dropped 20% in October

    This marijuana stock had a tough month last month. Here's what investors should know.

  • CNBC11 days ago

    Why people love CBD — the cannabis product that won't get you high

    The wave of marijuana legalization in recent years has more and more Americans toking up legally and experimenting with everything from candy to skincare products infused with cannabis. CBD products have become increasingly popular in recent years, as more and more producers market CBD as the new "it" drug for the health and wellness set — one that has been touted as a pain reliever and a treatment for anxiety, among other potential applications. Last year, consumer sales of CBD products topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years .

  • Assessing GW Pharmaceuticals’ Year-to-Date Performance
    Market Realist12 days ago

    Assessing GW Pharmaceuticals’ Year-to-Date Performance

    GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.

  • How Marijuana-Focused Biotech Companies Have Performed in 2018
    Market Realist12 days ago

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    Exploring Marijuana-Focused Biotech Companies' 2018 PerformancesMarijuana-focused biotech companies

  • Investopedia14 days ago

    Top Marijuana Stocks to Watch

    Pot stocks are blazing hot, but before you open your wallet to get a piece of the action, here are a few things that could help you.

  • Barrons.com14 days ago

    Marijuana Stocks Are Being Bought Up by Big Banks

    Bank of Montreal owned $73 million in U.S.-listed pot stocks at the end of the third quarter. CIBC and U.S. Bancorp owned $5 million and $2 million, respectively.

  • 9 High-Risk Stocks to Buy for Massive Rewards
    InvestorPlace15 days ago

    9 High-Risk Stocks to Buy for Massive Rewards

    Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.

  • 3 Smokin’ Hot Marijuana Stocks to Trade for the Next High
    InvestorPlace15 days ago

    3 Smokin’ Hot Marijuana Stocks to Trade for the Next High

    Amid all the ruckus of 2018 an investing thesis has emerged that has taken Wall Street by storm: Marijuana stocks surged almost like bitcoin did in its heyday.

  • ACCESSWIRE15 days ago

    CBD Stocks on The Rebound

    HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...

  • GlobeNewswire15 days ago

    GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its fourth quarter and year-end financial results for the period ending 30 September, 2018. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website ( shortly after the call.

  • The First Cannabis-Derived Drug Is Now on Pharmacy Shelves
    Motley Fool17 days ago

    The First Cannabis-Derived Drug Is Now on Pharmacy Shelves

    This cannabidiol-based therapy comes with a mammoth list price of $32,500 a year.

  • GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know
    Zacks19 days ago

    GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $145.71, marking a -1.05% move from the previous day.